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1. Introduction 
Kaposi’s sarcoma was first described in 1872 by Moritz Kaposi, a Vienna-based Hungarian 
dermatologist, as a rare multifocal angioproliferative tumour involving blood and lymphatic 
vessels in elderly men of Jewish origin (Kaposi, 1872). Before the AIDS epidemic three 
clinico-epidemiological forms with similar histological features have been described. The 
classic Kaposi’s sarcoma (KS) originally described by Kaposi is primarily a skin disease with 
a chronic indolent course that can sometimes regress spontaneously (Kaposi, 1872). Most of 
the cases occurred in elderly men of Mediterranean and Jewish origin. The African-endemic 
KS is seen in the indigenous population of sub-Saharan Africa (Franceschi & Geddes, 1995). 
It is also seen more commonly among male patients, but differs from the classic form in that 
it may affect a younger population and is more likely to spread to visceral organs and 
lymphatics. In addition, it has a variable clinical presentation ranging from a benign disease 
with few skin lesions to a widely disseminated disease associated with high morbidity and 
mortality (Franceschi & Geddes, 1995; Taylor et al 1971). Kaposi’s sarcoma seen in patients 
as a result of immunosuppression complicating organ transplantation may have chronic or 
progressive course and spontaneous remission after discontinuation of immunosuppressive 
therapy is observed in the majority of patients (Penn, 1979). 
The first description of AIDS-associated Kaposi’s sarcoma (AAKS) was in 1981, when 
Friedman-Kien et al (1981) reported some previously healthy young homosexual men with 
Kaposi's sarcoma involving lymph nodes, viscera, and mucosa as well as skin. This was 
associated with life-threatening opportunistic infections and a profound defect in cell-
mediated immunity. This aggressive and frequently fatal form of Kaposi's sarcoma is the 
most common cancer in patients with HIV infection (Schwartz, 2004). Before the discovery 
and widespread use of highly active antiretroviral therapy (HAART) KS was over 20,000 
times more common in AIDS patients than the general population (Engels et al 2006). 
However, several studies showed that HAART reduced the incidence of KS in high income 
countries (.Franceschi et al, 2008; Pipkin et al, 2011; Simard et al, 2011). The cumulative 
incidence of Kaposi sarcoma declined from 14.3% during 1980 to 1989, to 6.7% during 1990 
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to 1995, and to 1.8% during 1996 to 2006 (Simard et al, 2011). In a Swiss HIV cohort study, 
the overall KS incidence was 33.3 per 1000 person year (py) in 1984–1986 and did not change 
significantly in the subsequent periods until 1996–1998, when it fell to 5.1 (95% CI, 3.9–6.5) . 
The incidence further decreased to 1.4 per 1000 py in 1999–2001 and remained constant 
thereafter (Franceschi et al, 2008). In another recent pan-European multi-centre study, there 
was a decrease in the incidence rate of KS from 24.7 cases (95% CI 17.2–32.2) per 1000 py in 
1994 to 4.7 (95% CI 2.7–6.7) per 1000 py in 1997 and 1.7 (95% CI 0.7–3.4) per 1000 in recent 
years among HIV-infected individuals (Pipkin et al, 2011). In a report from Sao Paulo Brazil, 
a low income country, 17% of a cohort of patients on HAART was seropositive for human 
herpesvirus-8 of which only 2% developed AAKS in 5 years compared to 20% prevalence of 
AAKS detected in the same region before the HAART era (Yoshioka et al, 2004). In contrast, 
the incidence of KS has been steadily increasing in parallel with the AIDS epidemic in sub-
Saharan Africa (Bassett et al, 1995; Parkin et al, 2008; Sasco et al, 2010). In 2002, of 66,200 
estimated KS cases worldwide, 58,800 ware estimated to be in Africa (Parkin et al, 2008). Of 
these, about 39,500 cases in males and 17,100 cases in females occurred in sub-Saharan 
Africa compared to 102 males and 17 females in Northern Africa (Parkin et al, 2008). In areas 
such as Malawi, Uganda and Zimbabwe where Kaposi’s sarcoma was common before the 
AIDS epidemic, the incidence of this cancer has increased by about 20-times and it is now 
the most common cancer in males and second most common cancer in females (Sasco et al, 
2010). In Zimbabwe, the age-adjusted incidence of KS per 100,000 population was 2.3 in men 
and 0.3 in women before the AIDS epidemic, compared to 48 and 18, respectively, during 
the AIDS epidemic (Bassett et al, 1995). Recent studies conducted in South Africa and 
Rwanda found a clear association between HIV infection and KS with odd ratio ranging 
from 21.9 (95% CI 12.5–38.6) to 47.1 (95% CI 31.9–69.8) (Newton et al, 1995; Stein et al, 2008). 
Similarly, Newton et al (2001)in a study carried out in Kampala, Uganda found a higher risk 
of KS among HIV- infected compared to HIV-negative children with an odd ratio of 94.9 
(95% CI 28.5–315.3). 
Although the course of AAKS is variable most patients would eventually develop progressive 
and disseminated disease requiring active therapy. The choice of treatment is determined by 
the stage of KS, its rate of progression, the degree of immune competence and HIV associated 
diseases. Several therapeutic options are available for AAKS but the optimal therapy is still 
unclear. Highly active antiretroviral therapy including protease inhibitors may be the first 
treatment step for indolent slowly progressive disease (Martellotta et al, 2009). Following 
treatment with HAART, there may be complete remission   in patients with good 
immunological response and limited disease (Martellotta et al, 2009). However, recent studies 
indicate that there is no significant regression when patients with advanced, symptomatic 
AAKS are treated with HAART without simultaneous chemotherapy (Krown, 2004; Martin-
Carbonero 2004). A wide variety of chemotherapeutic agents, individually and in combination, 
have been evaluated for the treatment of AAKS. In high income countries, combination of 
vincristine, doxorubicin and bleomycin (VAB) that was considered the standard 
chemotherapy regimen for AAKS has been supplanted by liposomal anthracylines due to their 
higher efficacy and reduced toxicity (Ashish et al 2007; Cooley, 2007). In addition, the 
angiogenic nature of KS makes it particularly suitable for therapies based on targeted agents 
such as metalloproteinase inhibitors, angiogenesis inhibitors and tyrosine kinase inhibitors 
(Koon et al, 2011; Sullivan et al, 2009). In low income countries, the choice of therapeutic agents 
is limited to the combination of VAB or even more toxic drugs such as therlidomide because 
liposomal anthracyclines are not available or affordable (Makombe et al, 2009).   
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1.1 Aetiology and pathogenesis 
For a long time, the aetiology and pathogenesis of KS remained unclear. The discovery in 
1994 of KS-associated herpes virus (KSHV), also known as human herpes virus-8 (HHV-8), 
in cells isolated from an AAKS lesion was followed by molecular and epidemiological data 
confirming an aetiological link between this virus and all clinical forms of KS (Chang et al, 
1994; Hengge et al, 2002). Though infection with HHV-8 is not sufficient for tumour 
development, the virus has developed various mechanisms to manipulate host cell signal 
transduction, and thereby lead to the activation of numerous pro-growth and anti-apoptotic 
pathways. HIV-1 transactivation (Tat) protein is a short-term growth factor for KS 
(Guadalupe et al, 2011; Hassman et al, 2011). Tat protein through the mediation of IFN-γ,   
b-FGF and other cytokines has the capacity to induce endothelial cell proliferation and 
facilitate invasion of extracellular matrix (Hassman et al, 2011). In addition, it enhances 
HHV-8 infectivity for endothelial cells and increases its viral load by reactivating it from 
latent state (Guadalupe et al, 2011). On the other hand, HHV-8 activates nuclear receptors 
NF-kappa and NF-AT and this level of activation is synergistically increased by HIV-1 Tat 
protein (Guadalupe et al, 2011). Thus, infection with HHV-8 is associated with KS the risk 
for which correlates with HHV-8 viral load. However, for a given HHV-8 titre, the risk is 
greater in HIV-seropositive, as compared to HIV-seronegative individuals (Casper, 2011). 
Exceptions have been found in some parts of West Africa, South America and Australia 
where although the incidence of HHV-8 infection is high only few cases of KS are found 
(Ablashi et al 1999; Rezza et al, 2001). This indicates that other factors are important in the 
pathogenesis of KS. 
In Nigeria, the incidence of HIV/AIDS was estimated at 4.1 million and is on the downward 
trend (National Action Committee on AIDS (NACA) 2010). KS has become the most 
common malignant skin tumour with the disease appearing in areas where it did not exit in 
the past (Asuquo & Ebughe, 2009; Iregbu & Elegba, 2006). A report from Calabar South 
Eastern Nigeria showed that KS is the most common malignant skin tumour accounting for 
38.0% cases (Asuquo & Ebughe, 2009). Reports from Abuja and Benin both in Nigeria 
showed KS in 0.8% of newly diagnosed HIV infected patients compared to a prevalence of 
0.5% a decade earlier (Akinsete et al, 1998; Iregbu & Elegba, 2006; Onunu et al, 2007). Most 
of our patients present with extensive and advanced disease that usually required a 
combination of HAART and chemotherapy. This together with limited therapeutic facilities 
resulted in poor outcome of treatment (Ahmed et al, 2001; Asuquo & Ebughe, 2009). With 
improved AIDS awareness and access to HAART more patients are likely to present earlier. 
Our institution is one of the Federal Government HIV/AIDS designated treatment centre 
and we see patients from various parts of Nigeria. There is little information on the 
treatment and outcome of KS in HIV-1infected patients who have been treated with HAART 
in Africa. The objective of this study was to review the clinical features, treatment and 
outcome of AIDS –associated Kaposi’s sarcoma patients in our institution particularly in the 
context of increasing use of highly active antiretroviral therapy. We shall also highlight the 
difficulties in the evaluation and treatment of these patients. 
2. Patients and method 
This prospective study was carried out at Ahmadu Bello University Teaching Hospital 
Zaria, the premier referral and teaching hospital in Northern Nigeria. Patients with 
concurrent diagnosis of HIV infection and Kaposi’s sarcoma seen between January 2007 and 
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December 2010 were included. Only patients 18 years or more were included. Consent was 
obtained from each patient after counselling and at the time of taking blood sample, tissue 
specimen or taking photographs of accessible lesions. Permission for the study was also 
obtained from the hospital ethical committee.    
2.1 Patient’s evaluation and treatment 
Patients were assessed at the time of diagnosis of AAKS and at four to eight weekly 
intervals during follow-up. At each visit, weight, vital signs and Kaposi’s sarcoma 
symptoms were recorded, and a physical examination was performed. During evaluation 
efforts were made to discover the probable mode of HIV transmission to the patient. The 
dimension, number, appearance and sites of involvement of KS lesions were recorded. 
Lesions causing disfigurement were photographed. Tumour size was defined as the sum of 
the greatest diameters of each measurable tumour. The Karnofsky score status of the 
patients was also recorded. The tumour was staged according to AIDS Clinical Trials Group 
(ACTG) classification using the tumour (T), immune system (I) and systemic illness (S) 
(Krown et al, 1997). Tumour was defined as T0 if disease was confined to the skin and 
lymph nodes or oral involvement was confined to the hard palate, or T1 if there was 
pulmonary or gastrointestinal involvement, tumour associated oedema or ulceration, or 
extensive oral involvement. Cutaneous KS lesions confined to one anatomical area were 
classified as local while lesions involving two or more sites as disseminated. 
Morphologically the lesions were classified as macular, nodular and ulcerative. Tumour 
response was assessed by comparing lesion characteristics to the baseline tumour 
evaluations. Treatment responses were assessed according to ACTG criteria. A complete 
response (CR) was defined as the absence of any detectable residual disease, including 
tumour-associated oedema, persisting for at least four weeks. Partial response (PR) was 
defined as ≥50% decrease in the number or size of previously existing evaluable lesions 
lasting for at least four weeks without the appearance of new lesions or tumour-associated 
oedema. Stable disease (SD) was defined as any response that did not meet the criteria for 
progression or PR. Overall response rate was defined as both complete and partial response 
rates. Progressive disease (PD) was defined as ≥25% increase in the size of previously 
existing lesions or the appearance of new ones or the development of new or increasing 
tumour-associated oedema or effusion. Relapse was defined as the development of 
progressive disease in the presence of a documented CR, or PR.  
Screening test for HIV antibodies were performed by parallel testing using Enzyme-linked 
immunoabsorvent assay (ELISA) with Immunocomb II, HIV-1 and HIV-2 (M/S Orgenics, 
Israel) and Stat Pak (Trinity Biotech, Wicklow, Ireland). Positive test results from the two 
different kits were taken as confirmatory evidence of HIV antibodies.  The CD4 cell counts 
were performed using the Dynabeads method (Dynal Biotech LLC, Milwaukee, WI, USA). 
Patients that presented from 2008 to 2010 were screened with Stat Pak (Trinity Biotech, 
Wicklow, Ireland) and Bundi HIV-1 and HIV-2 (Bundi International Diagnostics, Abia, 
Nigeria) and confirmed with Western blot method. Their CD4 count was performed with 
Partec flow cytometre (Partec GmbH, Munster, Germany). Plasma HIV-1 RNA levels were 
measured with Roche-Ampiclor HIV-1 monitor test, (version 1.5 (Roche-Ampiclor-Roche 
Diagnostics, Branchburg, USA). Viral load less than 400 copies/mL was considered 
undetectable. Diagnosis of Kaposi’s sarcoma was based on histological examination of tissue 
specimens fixed in 10% formalin embedded in paraffin wax and stained with haematoxylin 
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and eosin. Special stains were employed in selected cases. Serum urea and electrolytes, liver 
function test and complete blood count with differential and platelet count were done at the 
time of diagnosis of AAKS and before administration of chemotherapy. Chest radiographs, 
ECG, abdominal ultrasound, faecal occult blood and gastrointestinal endoscopic 
examination were performed in appropriate cases. 
Our protocol for the treatment of AAKS has been presented previously (Ahmed et al, 2001). 
Following evaluation, patients were resuscitated and started on HAART which we defined 
as therapy consisting of at least three antiretroviral drugs in accordance with national 
guidelines (NACA, 2007). Our protocol recommends that patients with AAKS are started on 
HAART irrespective of CD4 count. Stable patients that have KPS of ≥40 and adequate bone 
marrow, renal and hepatic functions were then commenced on specific anti-KS 
chemotherapy. This consisted of six courses of three weekly cycles of vincristine 1.5mg/m2, 
doxorubicin 10mg/m2 and bleomycin 15mg/m2 by bolus intravenously. Treatments were 
delayed for up to two weeks for recovery from grade ≥3 neutropenia, thrombocytopenia or 
severe diarrhoea. Patients with relapse were treated with same course. Radiotherapy and 
surgical excision of localised lesions were performed in appropriate cases. Treatment 
complications and outcome were monitored. Patients were followed-up at four to eight 
weekly intervals until death or lost to follow-up.  
2.2 Statistical analysis 
We analysed data using SPSS statistical software (version 17.0, SPSS, Chicago IL). Data were 
reported as proportions, mean ± standard deviation (SD) or median (range). Categorical 
variables and proportions were compared by Fisher’s exact test while continuous variables 
were compared by Wilcoxon two-sample test. In patients that responded to treatment, the 
duration of response was summarised using Kaplan Meier method. Fisher’s exact test was 
used to test for agreement between the occurrence of clinical benefit and the presence of 
clinical response. Survival was calculated from the day of KS diagnosis until death or the 
date of last follow-up. Overall survival duration curves and duration of tumour response 
were plotted according to Kaplan-Meier method. Logistic regression modeling performed to 
identify independent determinants of survival and tumour response was done using the 
following clinicopathologic variables: age, sex, presence of comorbid condition, presence of 
systemic symptoms, KPS, stage of tumour, viral load and CD4 count at presentation. Risk 
factors were first analysed univariately, and the statistically significant variables were used 
to construct a multivariate model. Interactions were also analysed to confirm independence.  
We considered p ≤ 0.05 to be statistically significant. 
3. Results  
3.1 Patient’s characteristics 
During the period of study 7,155 patients with HIV infection were seen of which 98 (1.4%) 
had associated Kaposi’s sarcoma. The number of patients with AAKS increased steadily 
from 2007 to 2010 (table 1). Their ages ranged from 18 to 54 years (Figure 1), mean of 33.6 ± 
3.8 SD. Nine (9.2%) patients were less than 21 years old while 44 (44.9%) were in the third 
decade. There were 56 males and 42 females, male to female ration of 1.3:1. The male to 
female ratio decreased from 1.5:1 in 2007 to 1:1 in 2010. Females were younger than males 
(mean age of 27years vs. males 34; p< 0.04). Comorbid conditions were seen in 43 (43.9%) 
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patients including 20 (20.4%) pulmonary tuberculosis, 17 (17.3%) oral candidiasis, 15(15.3%) 
hypertension and 2 diabetes mellitus. Duration of symptoms of AAKS ranged from 1 to 13 
months, mean 5.7 ±1.2SD. Symptoms were present in 91 (92.9%) patients and included pain 
(62.2%), swelling of the limbs (figure 2) (52.6%) and cosmetic disability (31.6%). Seven (7.1%) 
patients had no symptoms of Kaposi’s sarcoma and the diagnosis was made during routine 
clinical evaluation (figure 3) at antiretroviral therapy (ART) clinic. Kaposi’s sarcoma was the 
AIDS defining disease in 64 (65.3%) patients while in the remaining 34 (34.7%) it was 
diagnosed between 1 and 15 months after the initial diagnosis of AIDS. Sixteen patients had 
used HAART for 1- 13 months at the time of diagnosis of AAKS. The KPS ranged from 20% 
to 100%, median of 60%. All the patients were heterosexual although 11 were men having 
sex with men (MSM). Patients on anti-retroviral therapy at the time of diagnosis had a mean 
CD4 count of 267± 65SD cell/mm3. Overall, the mean CD4 count at presentation was 165 
cells/mm3 (range: 26 – 875; 95% CI: 97 - 425). The mean HIV-1 viral load (VL) assessed in 71 
patients was 48,593 copies/mL (range: 200- 989,571; 95% CI: 28,593- 76,225).  
3.2 Tumour characteristics 
The anatomic distribution of AAKS lesions is shown in table 2. All patients had multiple 
lesions the lower limbs being most frequently involved (45.9%). In 20 (20.4%) patients, 
tumour was limited to extremities, with fungating and exophytic growth invading and 
destroying the subcutaneous and surrounding tissues including the underlying bones 
(Figure 4). Unusual sites including 7 conjunctiva, 9 penile and 12 vulva were also involved. 
Perineal involvement was more common in females. Visceral lesions included 3 rectal, 5 
intestinal and 2 gastric tumours. Tumour size ranged from 2.0 to 58.0cm, mean 29± 15.7SD. 
The histological type was mixed cellularity in 63 (64.3%) patients and anaplastic in 9 (9.2%). 
KS stage at presentation was T1, I1, S1 in 47 (48.0%); T1, I1, S0 in 22 (22.4%); T0, I0, S1, in 8 
(8.2%) and T0, I0, S0 in 21 (21.4%). Overall, 77 (78.6%) patients had poor prognosis stage 
comprising 38 (90.5%) females and 39 (69.6%) males (OR= 3.5, 95% CI 1.7–5.6, P < 0.01). 
Women also had more disseminated cutaneous AAKS lesions involving an increased 
number of lesions at multiple anatomical sites, compared to more localised lesions in males 
(OR =3.4, 95% CI = 1.7–5.5, P = 0.001). Despite the differences in age and disease severity 
between males and females, no gender-specific differences were observed in CD4 counts or 
plasma HIV-1 viral load. However, when males and females were analysed separately, there 
were significant correlations between the severity of KS and the degree of immune 
suppression as measured by CD4 count (χ2 test, P= 0.001) and between poor disease 
prognosis and immune suppression (P= 0.001) 
 
Year 
HIV infected patients AIDS associated Kaposi’s sarcoma patients 
No % No. 
% of HIV 
patients 
Male: 
Female 
2007 1667 23.3 20 1.2 1.5:1 
2008 1755 24.5 23 1.3 1.3:1 
2009 1837 25.7 25 1.4 1.2:1 
2010 1896 26.5 30 1.6 1:1 
Total 7155 100 98 1.4 1.3:1 
Table 1. Prevalence of HIV infection and AIDS-associated Kaposi’s sarcoma 
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Fig. 1. Age and sex distribution of patients with AIDS-associated Kaposi’s sarcoma 
 
 
 
 
Fig. 2. Nodular Kaposi’s sarcoma with swelling of the lower limb 
www.intechopen.com
  
Global View of HIV Infection 
 
110 
 
 
 
 
 
 
 
Fig. 3. Asymptomatic Kaposi’s sarcoma lesion discovered during routine clinical evaluation 
 
 
 
 
 
 
Site No. % 
Lower limb 45 45.9 
Trunk 37 37.8 
Lymph node 33 33.7 
Perineum 19 19.4 
Oropharynx 15 15.3 
Upper limb 13 13.3 
Visceral 9 9.2 
Other 6 6.1 
Table 2. Anatomical distribution of AIDS-associated Kaposi’s sarcoma lesions 
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Fig. 4. Fungating Kaposi’s sarcoma lesions of upper and lower limbs 
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Characteristics at 
presentation 
HAART alone HAART +VAB 
P -
value n Mean (SD) 
Standard 
error of 
mean 
n Mean (SD) 
Standard 
error of 
mean 
Age (years) 19 32.5 (4.7) 4.21 67 31.8 (7.5) 2.94 0.29 
Duration of 
symptom 
(months) 
19 3.5 (1.7) 0.84 67 3.9 (1.3) 1.25 0.14 
Viral load (x103 
copies/mL) 
10 503 (128.8) 17.50 41 512 (125.0) 15.9 0.15 
CD4 count 
(cell/uL) 
19 162 (56.4) 2.37 67 168 (55.8) 1.45 0.07 
Sex         0.75 
Male 12    42     
Female 7    25     
ACTG Stage          
Good 
prognosis 
4 (21.1%)   16 (23.9%)    
Poor 
prognosis 
15 (78.9%)   51 (76.1%)    
Time of 
diagnosis of KS 
        0.18 
At diagnosis 
of AIDS 
12 (63.2%)   43 (64.2%)    
After 
diagnosis of 
AIDS 
7 (36.8%)   24 (35.8%)    
SD= standard deviation; ACTG = AIDS clinical trials group; KS= Kaposi’s sarcoma 
HAART= highly active antiretroviral therapy; VAB= combination of Vincristine, Doxorubicin and 
Bleomycin 
Table 3. Characteristics of patients that were treated with HAART alone or HAART and 
VAB 
3.3 Treatment and outcome 
Overall, 67 (68.4%) patients were treated with both HAART and VAB of which 53 had 
completed six cycles. Of the 14 patients that did not complete anti-KS therapy, eight died in 
the course of treatment after two to five courses, treatment was stopped in two because of 
severe side effects and four were lost to follow-up (LTF). The median time to start 
chemotherapy after diagnosis of AAKS was three months (range 1 to 5months). Because of 
financial constraints, 19 (19.4%) patients had only antiretroviral therapy. The patients that 
had both HAART and VAB and those that had HAART alone had similar ACTG clinical 
stage, KPS and CD4 counts (table3). The remaining 12(12.2%) patients had only supportive 
care because of poor KPS (7) and refusal of consent (5). Two patients had limb amputation, 
five had excision of localised ulcerated lesions while 17(17.4%) had radiotherapy. Overall, 69 
(70.4%) patients had improvement of AAKS symptoms that lasted a median duration of ten 
months (range 3 months to 4 years). The cumulative tumour response is shown in figure 5. 
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Fifty four (80.6%) patients treated with HAART and VAB had tumour response compared to 
8 (42.1%) of those treated with HAART alone (p< 0.005). Patients treated with both HAART 
and VAB were more likely to have tumour response or stable disease (OR 2.7; CI: 1.8- 3.6) 
compared to those that had HAART alone (table 4). There was a positive correlation 
between symptoms control and tumour response (Pearson correlation coefficient, r = 0.35 
and r = 0.28; p < 0.05 by two tailed Fisher exact test). While haematotoxicity was the most 
frequent toxicity in both treatment groups, neutropenia grades three and four was higher in 
patients treated with both HAART and VAB (22.4%) compared to HAART alone (10.5%)(P < 
0.001). Digestive toxicity was frequently observed in both groups, with a higher rate of 
diarrhea in the HAART and VAB group. Five patients had peripheral neuropathy while two 
others had asymptomatic cardiomyopathy. These toxicities delayed chemotherapy by 1-2 
weeks in 15 patients.  
 
Patient’s response 
HAART 
alone (n=19) 
HAART +VAB 
(n=67) 
P -value 
Symptom control   0.003 
No.  (%) 10 (52.6) 59 (88.1)  
Median duration of symptoms 
control, months (range) 
5 (1- 13) 12 (5- 54) 0.001 
Overall tumour response 8 (42.1) 54 (80.6) 0.005 
Complete response 2 (10.5) 31 (46.3) 0.001 
Partial response 6 (31.6) 23 (34.3) 0.075 
Median duration of tumour  
response, months (range) 
5 (1-17) 11 (2- 54) 0.001 
Median time to relapse, months 
(range) 
3 (2.5-15) 9 (5-26) 0.001 
Treatment related complications    
No. (%) 7 (36.8) 38 (56.7) 0.015 
Median KPS (range)    
At diagnosis of KS 60 (30-90) 60 (30-90)  
3 months after diagnosis of KS 60 (20-90) 60 (40-90) 0.017 
Mortality at 6 months    
No. (%) 6 (31.5) 7 (10.4) 0.005 
KS= Kaposi’s sarcoma; KPS= Kernofsky performance score 
HAART= highly active antiretroviral therapy; VAB= combination of Vincristine, Doxorubicin and 
Bleomycin 
Table 4. Response of patients to treatment with HAART alone or HAART and VAB. 
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Fig. 5. Cumulative tumour response following treatment of AIDS-associated Kaposi’s 
sarcoma 
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Overall, median survival was 14 months from the time of diagnosis of AAKS. The median 
survival was 12 months for patients treated with HAART compared to 18 months for those 
treated with both HAART and VAB (figure 6). Overall 56 (57.1%) patients had significant 
improvement in quality of life. Seven (7.1%) patients died during their first admission in the 
hospital while additional 7 were lost to follow-up. At one year 34 (34.7%) patients had died, 
comprising of 12 (100%) patients that had only supportive treatment, 9(47.4.0%) of those 
treated with HAART and 13 (19.4%) treated with HAART and VAB (figure 6). Univariate 
analysis showed that females, poor ACTG stage, CD4 count <200 cells/mm3, viral load > 
21,000 copies/mL, and not using antiretroviral therapy were significantly associated with 
poorer survival (table 5). When these factors were subjected to multiple regression analysis, 
poor ACTG stage (p=0.015), viral load > 21,000 copies/mL (p=0.001), not using 
antiretroviral (p=0.005) and not using anticancer chemotherapy (p=0.003) were the 
significant independent factors associated with poorer survival.  Patient’s follow-up ranged 
from one month to four years. Fifty two (53.1%) patients were followed-up for one year. 
 
Variable 
Number 
of patients 
Death 
OR 95% CI 
P -
value No % 
Sex  
Male 56 21 37.5 1  
Female 42 20 47.6 1.4 1.2 – 2.9 0.049 
Age (years)  
1-20 9 4 44.4 1  
21-40 76 32 42.1 1.5 1.4 – 3.5  
41-60 13 5 38.5 1.3 1.1  –2.7 0.175 
Time of diagnosis of KS  
After diagnosis of AIDS 34 13 38.2 1  
As AIDS defining 
disease 
64 27 42.2 1.7 1.5 – 4.9 0.075 
ACTG stage  
Good prognosis 21 5 23.8 1  
Poor prognosis 77 35 45.5 4.8 3.7 – 12.4 0.005 
CD4 count (cells/mm3)  
>200 40 15 37.5 1  
≤200 58 25 43.1 2.4 1.6 – 3.9 0.016 
Viral load (copies/mL)  
0-20,000 11 2 18.2 1  
≥ 21,000 40 19 47.5 2.9 2.7 – 6.5 0.003 
Use of HAART  
Yes 86 28 32.5 1  
No 12 12 100.0 5.5 3.9 – 14.6 0.001 
Use of VAB  
Yes 67 18 26.8 1  
No 31 22 71.0 3.2 2.1 – 5.7 0.001 
OR= odd ratio; CI = confidence interval; ACTG = AIDS clinical trials group; KS= Kaposi’s sarcoma 
HAART= highly active antiretroviral therapy; VAB= combination of Vincristine, Doxorubicin and Bleomycin 
Table 5. Univariate analysis of factors related to mortality in patients with AIDS-associated 
Kaposi’s sarcoma 
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Fig. 6. Cumulative survival following treatment of patients with AIDS-associated Kaposi’s 
sarcoma 
4. Discussion  
To our knowledge, this is the largest study to date on the treatment and outcome of patients 
with AIDS-associated Kaposi’s sarcoma from Nigeria. The present study identified KS in 
1.4% of HIV-1 infected patients. The patients are young with female patients being relatively 
younger than males. The male to female ratio decreased from 1.5:1 in 2007 to 1:1 four years 
later. Majority of the patients (78.6%) presented with high tumour burden that was 
categorised as poor prognosis disease, while 20 (20.4%) had pulmonary tuberculosis. 
Simultaneous treatment with HAART and combination chemotherapy was carried out on 
67(68.4%) patients. This treatment was associated with significant morbidity but was the 
only chance for control of symptoms and prolonged survival. 
In high income countries the incidence of AAKS has decreased significantly from mid 1990s 
(Franceschi et al, 2008; Pipkin et al, 2011). This reduced AAKS incidence is due to wide 
spread use of HAART which has the effect of immune reconstitution and direct inhibitory 
effects on angiogenesis. In addition, there are safer sex practices and other preventive and 
therapeutic measures against HIV infection. Recently, Phatak et al (2010) from India 
identified no case of KS among 46 AIDS-associated cancers reviewed over 5 years. In 
another report from Thailand, the incidence was 0.026 per 100,000 despite high incidence of 
HIV infection because HHV-8 infection is low at 4.0% (Sriplung & Parkin, 2004). In the 
present study, there was progressive increase in prevalence of AAKS over the study period 
(table 1). In a previous report from our institution, 15 AAKS patients were seen from 1991 to 
1995 compared to 98 patients seen from 2007 to 2010 in the present study (Ahmed et al, 
2001). Overall, the prevalence of AAKS in this study was 1.4% which is lower than 1.6% 
reported from Jos, Nigeria and 3.4% from South Africa, but higher than 0.8% reported from 
www.intechopen.com
 Treatment of Kaposi’s Sarcoma in HIV-1 Infected Individuals 
 
117 
other centres in Nigeria (Agaba et al, 2009; Iregbu & Elegba, 2006; Chu et al 2010).  The high 
incidence of HHV-8 infection and limited access to HAART and other preventive measures 
explain in part the reason for increasing incidence of AAKS in sub-Saharan Africa. 
Prior to the HIV epidemic KS was a disease of middle-aged men (Penn, 1979; Taylor et al, 
1971). The mean age of 33.6 years in the present study is similar to that reported in other 
studies in our sub-region (Chu et al, 2010; Phipps et al, 2010). The lower age of these patients 
is probably due to the high risk behaviour and incidence of HIV infection is highest in the 
age group 20-40 years in sub-Saharan Africa. In addition, our female patients were younger 
than males. The finding that AAKS occurs at an earlier age in women when compared with 
men has been reported previously (Mosam et al, 2008; Phipps et al, 2010). In the present 
study, the proportion of KS patients was highest among women in their mid-20s who 
heterosexually acquired HIV-1 infection. This indicates that females acquire HIV-1 infection 
at an earlier age than males. Alternatively, immunosuppression from HIV infection and KS 
pathogenesis might progress more rapidly in females compared to males. Previous studies 
have shown that the age-specific distribution pattern for female KS was essentially similar to 
that previously reported for HIV-1 infection (Jombo et al, 2006). Therefore, the risk of 
developing AAKS is closely related to the epidemiology of HIV-1 infection in females.  
 
Variable Category OR 95% CI P-value 
Sex 
Female vs. 
Male 
1.8 1.5- 2.9 0.075 
ACTG stage 
Poor vs. 
Good 
prognosis 
5.3 2.2- 17.3 0.015 
CD4 count (cells/mm3) 
≤ 200 vs.  
> 200 
1.6 1.3- 3.8 0.075 
Viral load (copies/mL) 
≥ 21,000 vs. 
< 21,000 
3.1 2.6- 9.5 0.001 
Use of HAART No vs. Yes 2.8 2.3- 6.9 0.005 
Use of VAB No vs. Yes 1.9 1.5- 3.8 0.003 
OR= odd ratio; CI = confidence interval; ACTG = AIDS clinical trials group;  
HAART= highly active antiretroviral therapy; VAB= combination of Vincristine, Doxorubicin and 
Bleomycin 
Table 6. Multiple regression analysis of factors related to mortality in patients with AIDS-
associated Kaposi’s sarcoma 
In Western countries all forms of KS are more common among men than women (Simard et 
al, 2011; Martellotta et al 2009). This is similar to the findings in Africa before the advent of 
HIV infection (Sasco et al, 2010; Taylor et al, 1971). Among HIV-infected individuals other 
than MSM, reported incidence rates of KS are still higher in men in other studies (Kagu et al, 
2006; Sissolak & Mayaud, 2005). In a recent study from Brazil 94.4% of 107 AAKS patients 
were men, giving a male to female ratio of 18:1 (Yoshioka et al, 2004). The observations that 
a tumorigenic KS cell line could not be established in pregnant immunodeficient mice and 
that human chorionic gonadotropin (hCG) inhibited KS growth in-vitro suggested a possible 
biologic basis for the lower KS incidence among women (Lunardi-Iskandar et al, 1995; 
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Rabkin et al, 1995).  However, therapeutic trials with hCG have been inconclusive while 
studies in women with HIV infection revealed that pregnancy afforded no protection from 
KS development or dissemination (Rabkin et al, 1995). In our patients, the male to female 
ratio was 1.3:1 which decreased progressively from 1.5:1 in 2007 to 1:1 four years later. This 
is similar to 1.4:1 recently reported from South Africa (Chu et al, 2010). A report from Jos 
Nigeria revealed a reversal of the gender ratio from a male to female ratio of 10:1 about four 
decades ago to 1:1.4 (Agaba et al, 2009). The reason for the near equivalent distribution of 
AAKS cases among men and women in recent studies may be a reflection of the high 
proportion of HIV infected females with >60% of person living with the virus in Africa 
being women. Additionally, women are more frequently subjected to HIV testing as routine 
counselling and testing has been applied to perinatal settings, and this may lead to higher 
number of AAKS cases being identified among women. Finally, unlike in Western countries 
where MSM constitute a high proportion of AAKS cases, the heterosexual mode of HIV 
transmission in our patients mean that HHV-8 would be equally distributed among men 
and women. Therefore, the trend in increasing proportion of female patients with AAKS 
may continue until when females predominate.  
Patients in this study presented with extensive and disseminated disease with 78.6% having 
poor prognosis stage, a much higher proportion than reported from resource rich countries 
(Ashish et al, 2007; Krown 2004). Other reports from poor resource countries revealed that 
poor prognosis disease constitute 60-82% of cases (Agaba et al, 2009; Bassett et al, 1995; Phipps 
et al 2010). Cutaneous lesions were present in 64.7% of patients in this series followed in order 
of frequency by lymphadenopathy and visceral lesions. Moderate enlargement of peripheral 
lymph nodes is not uncommon in HIV infected patients. A biopsy of such nodes would often 
reveal a focus of KS, a finding that appears to have little clinical consequence (Krown 2004). 
However, 11 of our patients had massive generalised lympadenopathy in the absence of 
evidence of KS elsewhere.  In sub-Saharan Africa lymphadenopathy is comparatively common 
and has various causes including tuberculosis, lymphoma, KS and HIV infection.  There is a 
significant overlap in the clinical presentation of these diseases although each requires 
distinctly different treatment. Histology provides a reliable and cost effective definitive 
diagnosis since each disease can be distinctively diagnosed under the microscope. However, it 
has been suggested that co-existing lesions can be missed even in biopsy material if special 
stains for demonstration of microorganisms are not performed (Pantanowitz et al 2010). 
Involvement of the gastrointestinal tract (GIT) was seen in only nine of our patients. However, 
most patients with GIT KS are asymptomatic, and because the lesions are submucosal they are 
not visualized on contrast-enhanced radiographs (Kibria et al 2010). Previous studies showed 
that asymptomatic GIT lesions have little clinical consequences hence, endoscopy should be 
carried out only on symptomatic patients (Kibria et al, 2010; Sissolak & Mayaud, 2005). In our 
patients, KS involved multiple anatomical regions. The lower limbs were most frequently 
affected with an associated lymphoedema which may be extensive and disproportionate to the 
extent of cutaneous disease. This lymphoedema may result from tumour involvement of 
dermal lymphatics or from the production by KS cells of growth factors that increase vascular 
permeability (Feller et al, 2008). Additionally, HHV-8-induced exuberant proliferation of 
endothelial cells may lead to the occlusion of lymphatic vascular lumens leading to 
lymphoedema (Feller et al, 2008).  
In this as in other reports, at the time of diagnosis women had more widespread and 
advanced AAKS compared to men (Chu et al 2010; Meditz et al, 2007). It is probable that the 
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reason for the increased severity of AAKS in women is not related to virological or 
immunological differences since both men and women in our study had similar mean VL 
and mean CD4 counts. This is in agreement with studies from Zimbabwe and South Africa 
(Meditz et al, 2007; Mosam et al, 2008). Of special interest is a small cohort of 14 patients 
who were on HAART for 6-13 months at the time of diagnosis of KS. These patients had a 
median CD4 count of 375 cells/mm3 and undetectable HIV viral load. They required 
systemic therapy to control their KS but were more likely to have complete resolution of 
their tumours and demonstrated a trend towards better survival than patients having KS 
with lesser CD4 counts and detectable HIV viral loads. In the past, AAKS has been reported 
in African patients with CD4 counts of >350 cells /mm3 indicating that severe 
immunosuppression is not necessary for development of KS (Morgan et al, 2000). Similarly, 
recent reports from high income countries have identified a group of patients that 
developed AAKS despite effective and sustained HIV suppression and good immune 
system function (Crum-Cianflone et al, 2010; Mani et al, 2009; Maurer et al, 2007). This raises 
questions about the integrity of the immune system and its ability to control certain viruses 
in patients with long-standing HIV infection. It has been suggested that with the ageing of 
HIV infected patients those who are co-infected with HHV-8 may develop KS despite good 
control of HIV infection (Crum-Cianflone et al, 2010).  The impacts of AAKS on quality of 
life are varied. In our patients, extensive oedema of the lower limbs was associated with 
stiffness and pain that may interfere with walking while ulcerated tumours were infected 
and foul smelling. Lesions of the face and genitalia also have social and emotional 
consequences, including isolation because of obvious disfiguring lesions, and depression 
and anxiety from the constant visible reminder of illness. 
The disability and suffering associated with AAKS means that treatment to reduce 
symptoms and improve quality of life should be carried out promptly and efficiently. 
HAART is an essential treatment for all AAKS patients (Krown, 2004; Tirelli & Bernardi, 
2001). In patients with low tumour burden and slowly progressing disease, histological 
regression of existing KS lesions has been shown in response to HAART (Martellotta et al, 
2009). However, HAART alone can not effectively control all cases of KS and there may be 
initial tumour progression as part of the immunoreconstitution syndrome (Bower et al, 
2005). In addition, it is not possible to state with certainty what proportion of patients with 
AAKS will benefit from HAART alone, or what are the precise characteristics that can be use 
to identify such patients. In our patients as in others, HAART is an effective post-
chemotherapy maintenance treatment in patients with advanced and extensive disease that 
has been reduced significantly as a result of conventional chemotherapy (Cooley et al, 2007; 
Martin-Carbonero, 2004). The effects of HAART on Kaposi’s sarcoma are multifactorial and 
include inhibition of HIV replication, diminished production of HIV-1 transactivating 
protein Tat, reconstitution of immune response against HHV-8 and possibly direct 
antiangiogenic activity by inclusion of protease inhibitors (Tirelli & Bernardi, 2001). In the 
present study, decision to initiate systemic chemotherapy was based on the extent of 
Kaposi’s sarcoma in addition to other considerations such as patient KPS, end organ 
function, degree of immunosuppression, and other HIV comorbidities.  
Our patients were treated with a combination of vincristine, doxorubicin and bleomycin, 
similar to reports from other low income countries (Chu et al, 2010; Dedicoat et al, 2003).  In 
high income countries liposomal anthracyclines and taxanes are being used for treatment of 
AAKS due to higher efficacy and reduced toxicity (Ashish et al, 2007; Cooley et al, 2007). In 
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a meta- analysis comparing pegylated doxorubicin (PLD) and VAB among 499 patients, 
Dedicoat et al (2003) found a better response among the PLD group although there was no 
survival advantage by either group. However, liposomal anthracyclines are unlikely to be 
available or affordable in low income countries where the majority of AAKS patients live. In 
a recent analysis from Brazil, PLD was found to be associated with improved efficacy and 
less toxicity but in terms of cost effectiveness, the VAB regimen is the most rational 
treatment option for AAKS patients in poor resource settings (Vanni et al, 2006). Our results 
showed that six cycles of this regimen could produce a significant and quick response in 
symptomatic patients with advanced AAKS. Overall response rate of 80.6% in our patients 
compares favourably to 50% to 88% reported in other studies (Dedicoat et al, 2003; 
Makombe et al, 2008; Phipps et al, 2010). Differences in response rates are largely 
attributable to differences in the patient populations evaluated, the lack of strictly defined 
response criteria and variations in the dosing schedules used.  Of the 67 patients that had 
chemotherapy in this study, 52% had complete resolution of their disease within 36 months 
of diagnosis. This is similar to observed resolution rates of 44%-60% reported using similar 
regimen (Bihl et al, 2007; Nasti et al, 2000; Nguyen et al, 2008). However, we found the 
median time to complete resolution to be 9 months which is considerably longer than 5 
months previously reported (Bihl et al, 2007). This is provably because chemotherapy was 
not immediately started in many of our patients due to financial constraints. In the present 
study, both HAART and VAB were independently associated with complete resolution of 
tumour suggesting that even in the HAART era, chemotherapy plays a significant role in the 
treatment of advanced AAKS patients. In addition, HIV viral load was significantly 
associated with resolution of KS. This finding is consistent with other reports of AAKS 
improvement or resolution associated with significant decrease or undetectable HIV viral 
load (Nguyen et al, 2008). Indeed, it seems that controlling HIV viral load is essential for 
clinical improvement, disease resolution of KS, and perhaps decreased risk of relapse. In this 
as in other studies there was no association between CD4 T-cell count and KS response, 
suggesting that suppression of HIV replication plays a more vital role in the resolution of KS 
than immune reconstitution (Mosam et al, 2008; Iregbu & Elegba, 2006). In our patients, 
there was positive correlation between tumour response and clinical response, and the 
response was maintained for a significant period of time after discontinuation of 
chemotherapy. Clinical response was associated with improved quality of life as evidenced 
by control of fungating and foul smelling ulcers and improvement of pain, cosmetic 
appearance and KPS. In the present study, median survival was 18 months following 
chemotherapy compared to 12 months following HAART alone. Both VAB and HAART are 
independently associated with improved survival, similar to the Multicenter AIDS Cohort 
Study which demonstrated an 81% reduced risk of death for KS patients treated with 
HAART (Tam et al, 2002). Whilst CD4 count <200 cells/mm3 was associated with mortality 
on univariate analysis, it was not on multivariate analysis. This may be due to the effects of 
advanced KS disease (T1 and S1 stages) whose effects were stronger than CD4 count. 
The toxicities observed following chemotherapy in our patients are similar to those reported 
in other studies using same regimen and are well tolerated (Dedicoat et al, 2003; Guadalupe 
et al, 2011). In the absence of haemopoetic growth factors, cytotoxic chemotherapy was used 
cautiously in our patients to minimise the risk of bone marrow suppression that may lead to 
infectious complications. Bacterial infections which resulted from severe neutropenia 
secondary to chemotherapy were observed in three of our patients. Doxorubicin causes 
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significant bone marrow suppression which is at its nadir on day 14 after administration. 
This bone marrow suppression recovers slowly over 7-10 days but in an HIV infected 
individual the magnitude and duration of the bone marrow suppression may be longer, 
hence the need to wait for three weeks to allow the bone marrow to recover before the next 
cycle of chemotherapy is given. The selection of therapy for KS must take into account the 
potential benefit and adverse effects of treatment, interactions with other medications, and 
potential impact on underlying immunosuppression.  
When dealing with localised bulky or cosmetically disturbing lesions, radiotherapy is the 
most effective local therapy. In this as in other reports, irradiated lesions regress with 
treatment, but regrowth, after 6 months is common (Bih et al, 2007; Nguyen et al, 2008). In 
addition to providing effective palliation, radiotherapy is associated with minimal side 
effects. Although surgery is effective in excision of localised isolated lesions, heroic surgery 
is unjustified. Our study has several limitations. Among the patients that died, other risk 
factors for mortality such as tuberculosis were not independently considered hence the 
actual death due to KS were not isolated. In addition, some of our patients were lost to 
follow-up and a previous study indicates that about 40% of these patients were actually 
dead (Brinkhof et al, 2009). Similarly, because many patients lost to follow-up were treated 
with VAB, the beneficial effects of chemotherapy may be underestimated. Finally, follow-up 
of patients was difficult and inconsistent hence, it was not possible to monitor the timing of 
treatment outcome accurately. 
5. Conclusion   
In conclusion KS is not uncommon in patients with HIV-1 infection. The patients present 
with extensive and advanced disease that requires systemic treatment. All AAKS patients 
should receive HAART. In low income countries like ours, chemotherapy consisting of a 
combination of vincristine, doxorubicin and bleomycin should be given simultaneously with 
HAART to patients that can physiologically withstand such therapy. The usual number of 
cycles for effective therapy is six cycles. However, chemotherapy may continue for 1-2 
cycles beyond complete remission to maximise the chance of attacking all microscopic KS 
cells. Following successful treatment chemotherapy can be restarted for recurrent tumour. If 
KS continues to grow in the presence of effective HAART regimen, chemotherapy with VAB 
should be stopped and alternative treatment modalities should be instituted if possible, or 
else palliative KS management should be started. Palliative care for KS may include 
adequate pain relief, reduction of the size of tumours with radiotherapy and reduction of 
the offensive smell of ulcerated lesions with appropriate dressing argent. Prevention and 
treatment of other opportunistic infections is necessary as uncontrolled infections may 
stimulate KS progression probably due to production of angiogenic cytokines. Using this 
approach we achieved quick and prolonged tumour response in addition to improved 
quality of life as evidenced by symptoms control and improved cosmetic appearance and 
KPS. High satisfaction and reduced toxicities as well as availability, affordability and ease of 
administration of the drugs led to good patient’s compliance. This approach is 
recommended for treating AAKS patients in a poor resource setting. It is necessary to 
identify KS patients early in the disease when treatment is likely to provide significant 
benefits in terms of reducing the bulk of disease and improving long-term survival. 
However, early access to highly active antiretroviral therapy constitutes the best hope for 
the control of this stigmatizing and lethal disease in sub-Saharan Africa. With improvement 
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in the access to antiretroviral therapy in sub-Saharan Africa, it is necessary to designed 
studies that investigate the effects of cheaper and more widely available chemotherapeutic 
argents for the treatment of AIDS-associated Kaposi’s sarcoma among patients on highly 
active antiretroviral therapy. 
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